In transgenic mice, 3 to 6 weeks of oral AC-PS administration increased the proportion of CD4+ T cells and B cells within the
spleen. More specifically, there was an increase of Th1 CD4+ T cells and Be1 cells among spleen cells as observed by detection the of Type1/
Type2 marker molecules.